Skip to content

Effectiveness of Botox injection on chronic Plantar fasciitis

Effectiveness of Botulinium toxin A administration to Gastrecnemius muscle on pain and function among patients with chronic plantar fascitiis, Randomized control double blinded study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250220064788N1
Enrollment
42
Registered
2025-05-29
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar fascial fibromatosis. Plantar fascial fibromatosis

Interventions

Intervention 1: Intervention group:In the intervention group, 70 units of Botulinum Toxin A are injected into the upper third of the medial head of the gastrocnemius muscle. The drug, produced by the

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: People with a clinical diagnosis of chronic plantar fasciitis who have received supportive treatment for at least 2 months and have not responded to the treatment Presence of pain in the heel for at least two months with a VAS between numbers 3 and 7 (out of 10) at the time of examination

Exclusion criteria

Exclusion criteria: Suffering from a significant physical and mental illness that increases the risk of disrupting the study process Drug or Substance addiction Pregnancy or breastfeeding The presence of injury in the studied lower limb A history of Corticosteroid or PRP injection in the plantar fascia during at least the last 6 months History of Neuromuscular diseases such as Myasthenia gravis Allergy to botulinum toxin or eggs Suffering from orthopedic and medical problems that are contrary to the possibility of the person's participation in the study Heel pain with diagnoses other than plantar fasciitis The use of foot Orthoses since the time of entering the study Use of NSAID with anti-inflammatory dose during the study

Design outcomes

Primary

MeasureTime frame
Tenderness using VAS (Visual Analog Scale). Timepoint: Before injection and after eight weeks. Method of measurement: A 10-mm line will be drawn on paper, marked with '0' at one end and '10' at the other. Participants will be asked to indicate their overall pain level by marking a point on the line.;FAAM questionnaire. Timepoint: Before injection and after eight weeks. Method of measurement: Responses to the questionnaire and the total scores of the daily activities and sports subscales will be recorded.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDeclaration salehifar

Tehran University of Medical Sciences

Delaraa.salehifar@gmail.com+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026